Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Atripla to Complera in Virologically Suppressed HIV-1 Patients
NCT01286740Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 (FDA Snapshot Analysis). Started Jan 2011; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01286740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286740.